c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.
Huo Q, Lv J, Zhang J, Huang H, Hu H, Zhao Y, Zhang X, Wang Y, Zhou Y, Qiu J, Ye Y, Huang A, Chen Y, Qin L, Qin D, Li P, Cai G.
Huo Q, et al. Among authors: hu h.
Cytotherapy. 2023 Oct;25(10):1037-1047. doi: 10.1016/j.jcyt.2023.06.004. Epub 2023 Jul 11.
Cytotherapy. 2023.
PMID: 37436338
Free article.